Insights

Gathering insights about Invivyd…

Similar companies to Invivyd

Invivyd Tech Stack

Invivyd uses 8 technology products and services including OneTrust, Salesforce, Nasuni, and more. Explore Invivyd's tech stack below.

OneTrust
Cookie Compliance
Salesforce
Customer Relationship Management
Nasuni
Document Management Systems
Microsoft Excel
Editors
OneDrive
File Sharing
ADP
Human Resource Management System
UNIX
Operating Systems
Windows 10
Operating Systems

Media & News

Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine
NEW HAVEN, Conn., June 16, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced enrollment of participants in its Phase 3 LIBERTY clinical trial is complete. The trial is comparing the safety and tolerability of the company's investigational COVID-19 monoclonal antibody VYD2311 with an mRNA COVID-19 vaccine. The trial is also evaluating the safety and immune response when both are given together. VYD2311 is being developed as an alternative to vaccines for preventing COVID-19. The LIBERTY study is a randomized, double-blind trial involving healthy adults. A primary endpoint of the trial is to assess the side effects and tolerability of COVID antibody versus vaccine through Day six, for a total of seven days. Invivyd expects to report initial results from the study in the third quarter of 2026. These results may be released alongside data from the company's pivotal DECLARATION clinical trial.
Jun 16, 2026 | www.globenewswire.com
Invivyd doses first participants in Phase 3 COVID-19 trial
Invivyd Inc (NASDAQ:IVVD) has dosed the first participants in its LIBERTY Phase 3 trial, a study testing the company's monoclonal antibody VYD2311 for the prevention of COVID-19 against and alongside an mRNA vaccine. The randomized, double-blind trial is evaluating the safety, tolerability and immune response of VYD2311 on its own, an mRNA COVID-19 vaccine on its own, and VYD2311 given together with a COVID-19 vaccine in healthy adults, the New Haven, Connecticut-based company said.
Jun 09, 2026 | www.proactiveinvestors.com
Invivyd doses first participants in Phase 3 COVID-19 trial
Invivyd Inc (NASDAQ:IVVD) has dosed the first participants in its LIBERTY Phase 3 trial, a study testing the company's monoclonal antibody VYD2311 for the...
Jun 09, 2026 | www.proactiveinvestors.com
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration
NEW HAVEN, Conn., June 09, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the first participants have been dosed in the LIBERTY Phase 3 clinical trial, a randomized, double-blind study that is evaluating the safety and tolerability and immunology of VYD2311 alone, an mRNA COVID-19 vaccine alone, and VYD2311 co-administered with a COVID-19 vaccine in healthy adults. VYD2311 is Invivyd's vaccine-alternative monoclonal antibody (mAb) investigational candidate for the prevention of COVID-19. Depending on study recruitment rate, Invivyd expects to report topline data from the LIBERTY trial in Q3 2026, to accompany anticipated data from the pivotal DECLARATION clinical trial.
Jun 09, 2026 | www.globenewswire.com
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HAVEN, Conn., June 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on June 1, 2026, Invivyd granted 17 newly hired non-executive employees options to purchase an aggregate of 513,500 shares of its common stock, each as a material inducement for each employee's entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.
Jun 03, 2026 | www.globenewswire.com
Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID
NEW HAVEN, Conn., June 01, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the completion of enrollment in the DECLARATION trial evaluating VYD2311, an investigational monoclonal antibody candidate for the prevention of symptomatic COVID-19. DECLARATION is the company's Biologics License Application (BLA)-enabling, Phase 3 randomized, placebo-controlled clinical trial to evaluate VYD2311 efficacy and safety in prevention of symptomatic COVID in a broad population of participants including adults and adolescents. Top-line results continue to be expected in approximately late Q3 2026.
Jun 01, 2026 | www.globenewswire.com
Invivyd to Participate in Upcoming Investor Events
NEW HAVEN, Conn. , May 27, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will participate in upcoming investor events in June: 2026 Jefferies Global Healthcare Conference in New YorkFireside Chat Date and Time: Wednesday, June 3, 2026 4:55 p.
May 27, 2026 | www.globenewswire.com

Invivyd's Email Address Formats

Invivyd uses at least 2 format(s):

Invivyd Email Formats	Example	Percentage
FLast@invivyd.com	JDoe@invivyd.com	96%
First.Last@invivyd.com	John.Doe@invivyd.com	4%
First.Last@adagiotx.com	John.Doe@adagiotx.com	71%
FLast@adagiotx.com	JDoe@adagiotx.com	16%
FirstLast@adagiotx.com	JohnDoe@adagiotx.com	12%
FirstLas@adagiotx.com	JohnDoe@adagiotx.com	1%

Frequently Asked Questions

Where is Invivyd's headquarters located?

Invivyd's main headquarters is located at 209 Church Street New Haven, Connecticut 06510 United States. The company has employees across 1 continents, including North America.

What is Invivyd's stock symbol?

Invivyd is a publicly traded company; the company's stock symbol is IVVD.

What is Invivyd's official website and social media links?

Invivyd's official website is invivyd.com and has social profiles on LinkedIn Crunchbase.

What is Invivyd's SIC code NAICS code?

Invivyd's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Invivyd have currently?

As of June 2026, Invivyd has approximately 168 employees across 1 continents, including North America. Key team members include Chief Human Resources Officer: J. G.Chief Medical Officer: M. M.Chief Legal Officer And Corporate Secretary: J. A.. Explore Invivyd's employee directory with LeadIQ.

What industry does Invivyd belong to?

Invivyd operates in the Biotechnology Research industry.

What technology does Invivyd use?

Invivyd's tech stack includes OneTrustSalesforceNasuniMicrosoft ExcelOneDriveADPUNIXWindows 10.

What is Invivyd's email format?

Invivyd's email format typically follows the pattern of FLast@invivyd.com. Find more Invivyd email formats with LeadIQ.

How much funding has Invivyd raised to date?

As of June 2026, Invivyd has raised $58M in funding. The last funding round occurred on Aug 20, 2025 for $58M.

When was Invivyd founded?

Invivyd was founded in 2020.

Invivyd

Q: What is Invivyd's official website and social media links?

Invivyd's official website is invivyd.com. Invivyd has social profiles on LinkedIn.

Q: How many employees does Invivyd have currently?

Invivyd has approximately 168 employees.

Q: What technology does Invivyd use?

Invivyd's tech stack includes C++, Base SAS, Django, Underscore.js, GoDaddy.

Q: What is Invivyd's NAICS code?

Invivyd's NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Biotechnology ResearchConnecticut, United States51-200 Employees

Invivyd, Inc. (Nasdaq: IVVD) creates medicines that are more potent and resistant to virus evolution than the human immune system. We deploy a proprietary integrated technology platform unique in the industry to assess, monitor, drug and adapt to create best in class antibodies.

Company Overview

Headquarters: 209 Church Street New Haven, Connecticut 06510 United States
Website: invivyd.com
SIC Code: 8733 - Noncommercial Research Organizations
Stock Symbol: IVVD
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2020
Employees: 51-200

Media & News

Funding & Financials

$58M
Invivyd has raised a total of $58M of funding over 5 rounds. Their latest funding round was raised on Aug 20, 2025 in the amount of $58M.
$50M$100M
Invivyd's revenue is estimated to be in the range of $50M$100M

Funding & Financials

$58M
Invivyd has raised a total of $58M of funding over 5 rounds. Their latest funding round was raised on Aug 20, 2025 in the amount of $58M.
$50M$100M
Invivyd's revenue is estimated to be in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Invivyd

Influitive

Annex Cloud

Wootric

Amplifinity

Gainsight

Lumoa

CustomerGauge

Yotpo

Canny

CustomerSuccessBox

Invivyd Tech Stack

Media & News

Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine

Invivyd doses first participants in Phase 3 COVID-19 trial

Invivyd doses first participants in Phase 3 COVID-19 trial

Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID

Invivyd to Participate in Upcoming Investor Events

Invivyd's Email Address Formats

Frequently Asked Questions

Where is Invivyd's headquarters located?

What is Invivyd's stock symbol?

What is Invivyd's official website and social media links?

What is Invivyd's SIC code NAICS code?

How many employees does Invivyd have currently?

What industry does Invivyd belong to?

What technology does Invivyd use?

What is Invivyd's email format?

How much funding has Invivyd raised to date?

When was Invivyd founded?

Invivyd

Company Overview

Media & News

Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine

Invivyd doses first participants in Phase 3 COVID-19 trial

Invivyd doses first participants in Phase 3 COVID-19 trial

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?